Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Metabolic Health

Dietary fat differentially influences the lipids storage on the adipose tissue in metabolic syndrome patients

A. Camargo; M. E. Meneses; P. Perez-Martinez; J. Delgado-Lista; Y. Jimenez-Gomez; C. Cruz-Teno; F. J. Tinahones; J. A. Paniagua; F. Perez-Jimenez; H. M. Roche; M. M. Malagon; J. Lopez-Miranda Dietary fat differentially influences the lipids storage on the adipose tissue in metabolic syndrome patients European Journal of Nutrition
Genetics Metabolic Syndrome

Exposure-response analyses of liraglutide 3.0 mg for weight management

J. P. Wilding; R. V. Overgaard; L. V. Jacobsen; C. B. Jensen; C. W. le Roux Exposure-response analyses of liraglutide 3.0 mg for weight management Diabetes Obes Metab

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis

P. M. Ryan; S. Seltzer; N. E. Hayward; D. A. Rodriguez; R. T. Sless; C. P. Hawkes Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis J Pediatr

Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation

L. A. Powell; P. Crowe; C. Kankara; J. McPeake; D. R. McCance; I. S. Young; E. R. Trimble; A. McGinty Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation Clinical science
Insulin Resistance & Diabetes

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

X. Pi-Sunyer; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; D. C. Lau; C. W. le Roux; R. Violante Ortiz; C. B. Jensen; J. P. Wilding A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

W. D. Porter; P. R. Flatt; C. Hölscher; V. A. Gault Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice International Journal of Obesity
Insulin Resistance & Diabetes

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

V. Pathak; P. R. Flatt; N. Irwin Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes Peptides
Insulin Resistance & Diabetes

Liraglutide: another reason to target prediabetes?

C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Insulin Resistance & Diabetes

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial

D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Insulin Resistance & Diabetes

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page26 Page27 Page28 … Page54 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2025 ASOI